Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2006

01.11.2006 | Original Paper

The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma

verfasst von: Hui Zhang, Qing-Hai Ye, Ning Ren, Lei Zhao, Yan-Fang Wang, Xin Wu, Hui-Chuan Sun, Lu Wang, Bo-Heng Zhang, Yin-Kun Liu, Zhao-You Tang, Lun-Xiu Qin

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

We aimed to evaluate the prognostic value of preoperative plasma osteopontin (OPN) levels in 101 patients with hepatocellular carcinoma (HCC) who underwent liver resection. Plasma OPN levels were detected by ELISA. The association of plasma OPN levels of patients with clinicopathological characteristics, tumor recurrence, and survival was analyzed. The median plasma OPN level of patients was 176.90 ng/ml (range 13.73–780.00 ng/ml), which was significantly higher than that of 24 healthy volunteers (63.74 ng/ml, range 12.20–122.32 ng/ml). Plasma OPN levels were significantly different in patients with different numbers of tumor nodules (168.18 and 217.11 ng/ml for single and multiple nodules, respectively; P = 0.002), different Edmondson’s grades (201.24, 168.36, and 503.58 ng/ml for grades I, II, and III/IV, respectively; P = 0.015), and different TNM stages (168.16, 167.54, and 216.18 ng/ml for stages I, II, and III/IV, respectively; P = 0.016). Significantly higher plasma OPN levels were found in patients with a recurrence of HCC after resection, compared with those without recurrence (213.55 versus 153.70 ng/ml; P = 0.0013). A higher plasma OPN level was a leading independent prognostic factor for both overall survival (OS) and disease-free survival (DFS) in univariate and multivariate Cox models. This suggests that the preoperative plasma OPN level can be used as a predictive marker for HCC recurrence and may be helpful to assess the prognosis of patients with HCC after surgery.
Literatur
Zurück zum Zitat Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521PubMed Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521PubMed
Zurück zum Zitat Bautista DS, Saad Z, Chambers AF, Tonkin KS, O’Malley FP, Singhal H, Tokmakejian S, Bramwell V, Harris JF (1996) Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 29:231–239PubMedCrossRef Bautista DS, Saad Z, Chambers AF, Tonkin KS, O’Malley FP, Singhal H, Tokmakejian S, Bramwell V, Harris JF (1996) Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 29:231–239PubMedCrossRef
Zurück zum Zitat Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457PubMedCrossRef Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457PubMedCrossRef
Zurück zum Zitat Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO, Chambers AF (2005) Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biol Ther 4:1336–1341PubMedCrossRef Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO, Chambers AF (2005) Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biol Ther 4:1336–1341PubMedCrossRef
Zurück zum Zitat Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 88:912–920PubMedCrossRef Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 88:912–920PubMedCrossRef
Zurück zum Zitat Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G (2003) Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20:437–444PubMedCrossRef Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G (2003) Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20:437–444PubMedCrossRef
Zurück zum Zitat Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753–758PubMedCrossRef Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753–758PubMedCrossRef
Zurück zum Zitat Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311–323PubMedCrossRef Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311–323PubMedCrossRef
Zurück zum Zitat Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS (1997) Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14:1581–1588PubMedCrossRef Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS (1997) Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14:1581–1588PubMedCrossRef
Zurück zum Zitat Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRef Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRef
Zurück zum Zitat Crawford HC, Matrisian LM, Liaw L (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58:5206–5215PubMed Crawford HC, Matrisian LM, Liaw L (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58:5206–5215PubMed
Zurück zum Zitat Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723–749PubMedCrossRef Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723–749PubMedCrossRef
Zurück zum Zitat De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J (1998) Trends in primary liver cancer. Lancet 351:215–216PubMedCrossRef De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J (1998) Trends in primary liver cancer. Lancet 351:215–216PubMedCrossRef
Zurück zum Zitat Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465PubMedCrossRef Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465PubMedCrossRef
Zurück zum Zitat El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef
Zurück zum Zitat Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535PubMedCrossRef Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535PubMedCrossRef
Zurück zum Zitat Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMed Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMed
Zurück zum Zitat Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y (2006) Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118:2255–2261PubMedCrossRef Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y (2006) Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118:2255–2261PubMedCrossRef
Zurück zum Zitat Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632PubMedCrossRef Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632PubMedCrossRef
Zurück zum Zitat Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S (2002) Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52:19–24PubMedCrossRef Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S (2002) Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52:19–24PubMedCrossRef
Zurück zum Zitat He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134PubMedCrossRef He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134PubMedCrossRef
Zurück zum Zitat Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95:506–512PubMedCrossRef Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95:506–512PubMedCrossRef
Zurück zum Zitat Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao YZ (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646–4652PubMedCrossRef Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao YZ (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646–4652PubMedCrossRef
Zurück zum Zitat Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer Statistics 2003. CA Cancer J Clin 53:5–26PubMed Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer Statistics 2003. CA Cancer J Clin 53:5–26PubMed
Zurück zum Zitat Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671–1679CrossRef Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671–1679CrossRef
Zurück zum Zitat Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, Maeda M, Nakamoto A, Owan I, Kuba M, Kudeken N, Azuma M, Yara S, Shinzato T, Higa F, Tateyama M, Kadota JI, Mukae H, Kohno S, Uede T, Saito A (2003) High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 167:1355–1359PubMedCrossRef Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, Maeda M, Nakamoto A, Owan I, Kuba M, Kudeken N, Azuma M, Yara S, Shinzato T, Higa F, Tateyama M, Kadota JI, Mukae H, Kohno S, Uede T, Saito A (2003) High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 167:1355–1359PubMedCrossRef
Zurück zum Zitat Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67PubMed Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67PubMed
Zurück zum Zitat Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K (2004) Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res 29:202–206PubMedCrossRef Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K (2004) Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res 29:202–206PubMedCrossRef
Zurück zum Zitat Medico E, Gentile A, Lo Celso C, Williams TA, Gambarotta G, Trusolino L, Comoglio PM (2001) Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 61:5861–5868PubMed Medico E, Gentile A, Lo Celso C, Williams TA, Gambarotta G, Trusolino L, Comoglio PM (2001) Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 61:5861–5868PubMed
Zurück zum Zitat Oates AJ, Barraclough R, Rudland PS (1996) The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13:97–104PubMed Oates AJ, Barraclough R, Rudland PS (1996) The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13:97–104PubMed
Zurück zum Zitat O’Regan A, Fleming C (2002) Comment on: JAMA 2002, 287:1671–1679. Osteopontin as a biomarker for ovarian cancer. JAMA 287:3208–3210 O’Regan A, Fleming C (2002) Comment on: JAMA 2002, 287:1671–1679. Osteopontin as a biomarker for ovarian cancer. JAMA 287:3208–3210
Zurück zum Zitat Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127PubMedCrossRef Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127PubMedCrossRef
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
Zurück zum Zitat Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29PubMedCrossRef Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29PubMedCrossRef
Zurück zum Zitat Qin LX, Tang ZY (2004) Recent progresses in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a literatures review. J Cancer Res Clin Oncol 130:497–513PubMedCrossRef Qin LX, Tang ZY (2004) Recent progresses in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a literatures review. J Cancer Res Clin Oncol 130:497–513PubMedCrossRef
Zurück zum Zitat Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881PubMedCrossRef Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881PubMedCrossRef
Zurück zum Zitat Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed
Zurück zum Zitat Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I (2003) Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 123:263–270PubMedCrossRef Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I (2003) Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 123:263–270PubMedCrossRef
Zurück zum Zitat Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605–611PubMed Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605–611PubMed
Zurück zum Zitat Shijubo N, Uede T, Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11:135–146PubMed Shijubo N, Uede T, Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11:135–146PubMed
Zurück zum Zitat Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, London Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, London
Zurück zum Zitat Sulzbacher I, Birner P, Trieb K, Lang S, Chott A (2002) Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441:345–349PubMedCrossRef Sulzbacher I, Birner P, Trieb K, Lang S, Chott A (2002) Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441:345–349PubMedCrossRef
Zurück zum Zitat Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187–196PubMedCrossRef Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187–196PubMedCrossRef
Zurück zum Zitat Terashi T, Aishima S, Taguchi K, Asayama Y, Sugimachi K, Matsuura S, Shimada M, Maehara S, Maehara Y, Tsuneyoshi M (2004) Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int 24:38–45PubMedCrossRef Terashi T, Aishima S, Taguchi K, Asayama Y, Sugimachi K, Matsuura S, Shimada M, Maehara S, Maehara Y, Tsuneyoshi M (2004) Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int 24:38–45PubMedCrossRef
Zurück zum Zitat Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMed Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMed
Zurück zum Zitat Tuck AB, O’Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502–508PubMedCrossRef Tuck AB, O’Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502–508PubMedCrossRef
Zurück zum Zitat Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79:127–132PubMedCrossRef Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79:127–132PubMedCrossRef
Zurück zum Zitat Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC (2005) Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26:741–751PubMedCrossRef Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC (2005) Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26:741–751PubMedCrossRef
Zurück zum Zitat Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed
Zurück zum Zitat Wu Y, Denhardt DT, Rittling SR (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83:156–163PubMedCrossRef Wu Y, Denhardt DT, Rittling SR (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83:156–163PubMedCrossRef
Zurück zum Zitat Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416–423PubMedCrossRef Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416–423PubMedCrossRef
Zurück zum Zitat Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH (2001) Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 91:1479–1486PubMedCrossRef Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH (2001) Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 91:1479–1486PubMedCrossRef
Metadaten
Titel
The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma
verfasst von
Hui Zhang
Qing-Hai Ye
Ning Ren
Lei Zhao
Yan-Fang Wang
Xin Wu
Hui-Chuan Sun
Lu Wang
Bo-Heng Zhang
Yin-Kun Liu
Zhao-You Tang
Lun-Xiu Qin
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2006
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-006-0119-3

Weitere Artikel der Ausgabe 11/2006

Journal of Cancer Research and Clinical Oncology 11/2006 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.